Vimarsana
Biggest News Aggregation in the World

Page 11 - Aser Surgery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aser Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aser Surgery Today - Breaking & Trending Today

Driving Accessibility in HealthTech: 3 Things Founders should Consider for Thoughtful AI Implementation in 2024 - Vimarsana News

Driving Accessibility in HealthTech: 3 Things Founders should Consider for Thoughtful AI Implementation in 2024

The benefits of artificial intelligence in healthcare are apparent. With careful planning, we can ensure that these developments benefit everyone, leaving no one behind in the goal of a healthier and more equal future.

Is AI in Prior Authorization Promising or Dangerous? - Vimarsana News

Is AI in Prior Authorization Promising or Dangerous?

AI can improve the prior authorization process, but there needs to be more transparency, experts said during a recent panel held by KFF.

Women's Health Startup Pledges $10M for Women's Health Research - Vimarsana News

Women's Health Startup Pledges $10M for Women's Health Research

Perelel's $10 million pledge comes in the form of product donations and funding grants and will go to the Magee-Womens Research Institute and the Good+Foundation through 2027.

Network With Healthcare Investors at MedCity INVEST 2024! - Vimarsana News

Network With Healthcare Investors at MedCity INVEST 2024!

The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!

GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact - Vimarsana News

GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.